UCHL1 (Ubiquitin Carboxy-terminal Hydrolase L1) (human) (rec.)

CHF 358.00
In stock
YIF-LF-P03110.1 mgCHF 358.00
More Information
Product Details
Synonyms UCHL1; PGP9.5; UCH-L1; PGP 9.5; EC=; Ubiquitin Thioesterase L1; Neuron Cytoplasmic Protein 9.5; Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1
Product Type Protein
Source/Host E. coli
Crossreactivity Human
Biological Activity

Activity has not been tested.

Purity ≥90% (SDS-PAGE)
Formulation Lyophilized from 50mM Tris, pH8.0 / 10mM GSH.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability After reconstitution, store at -80°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a deubiqutinating enzyme. Ubiquitin UCHL1, also known as PGP9.5, is a protein of 223 amino acids and one of the most abundant proteins in the brain (1~2% of the total soluble protein). Although it was originally characterized as a deubiquitinating enzyme recent studies indicate that it also functions as a ubiquitin (Ub) ligase and a mono-Ub stabilizer. A large amount of mono-Ub is tightly associated with UCHL1, inhibiting the degradation of mono-Ub in the brain. The precise regulation of UCHL1 is essential for neurons to survive and to maintain their proper function. UCHL1 is involved in the pathogenesis of Parkinson’s disease (PD) and Alzheimer's disease (AD). Down-regulation and extensive oxidative modification of UCHL1 have been observed in the brains of AD patients as well as PD patients. A post-translational modification of UCHL1 that controls the function of UCHL1 is mono-ubiquitination. It occurs reversibly to a lysine residue near the active site of UCHL1.

Product References

1) Setsuie Rand Wada K, (2007) Neurochem Int. 51(2-4):105-111. (General)
2) Gong B and Leznik E, (2007) Drug News Perspect. 20(6):365-370. (General)
3) Betarbet R et al. (2005) Exp Neurol. 191 Suppl 1:S17-27. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.